Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
Solid Biosciences Inc., a life sciences company that acquired UF startup AavantiBio, announced that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for SGT-212, the Company’s, AAV-based gene therapy candidate for the treatment of Friedreich’s ataxia (FA).
Solid Biosciences Announces FDA IND Clearance for First-in-Industry Dual Route of Administration Gene Therapy To Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia
Solid Biosciences Inc., a biotechnology company that acquired UF startup AavantiBio, announced that the U.S. FDA has cleared its Investigational New Drug application for SGT-212 for the treatment of Friedreich’s ataxia.
Solid Biosciences Announces Collaboration With Mayo Clinic To Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene Therapies
Solid Biosciences Inc., which acquired UF Startup AavantiBio, has partnered with Mayo Clinic to advance an AAV gene therapy platform for next-generation treatments targeting genetic cardiomyopathies and channelopathies linked to sudden cardiac death.
Solid Biosciences Shares Updates on Inspire Duchenne Clinical Trial of SGT-003
Solid Biosciences, a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases that acquired UF startup AavantiBio, shared updates on the INSPIRE DUCHENNE clinical trial for their next-generation AAV micro-dystrophin gene therapy candidate, SGT-003, for the treatment of Duchenne.
JPMorgan Upgrades Solid Biosciences Stock, Sees Growth Potential
JPMorgan upgraded Solid Biosciences stock, a biotechnology company that acquired UF startup AavantiBio, from Neutral to Overweight, and increased the price target to $15.00 from the previous $10.00. The firm's decision reflects a positive outlook on the company's prospects, particularly with upcoming developments expected in the fourth quarter.
Solid Biosciences Joins the Russell 3000® Index
Solid Biosciences Inc., a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases that acquired UF startup AavantiBio, announced it has been added to the broad-market Russell 3000® Index as part of the annual reconstitution, effective July 1st, 2024.
